Back to search
Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Hepatocellular Carcinoma With Portal Vein Tumor Thrombus trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Hepatocellular Carcinoma With Portal Vein Tumor Thrombus trials you may qualify forThis single-center, prospective, single-arm Phase II clinical trial is designed to evaluate the efficacy and safety of combining hepatic artery infusion chemoth…
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, being the third leading cause of cancer-related death worldwide, with approximately 745…
The goal of this prospective, single-arm, multi-center Phase II clinical trial is to evaluate the clinical efficacy and safety of QL1706 combined with bevacizum…
This study is an open-label, single-arm prospective clinical trial that evaluates the efficacy and safety of neoadjuvant intensity-modulated radiotherapy combin…
We will give an anticoagulant against portal vein thrombosis, and watch for the results.
Although resection provided survival benefit for selected HCC patients with PVTT, the recurrence rate is still high for those patients. It is still unknown whet…
This study is investigator initiated, single-institution, prospective, phase 2 open-label study to determine the efficacy and safety of combination therapy of a…
Patients with hepatocellular carcinoma (HCC) complicated by Vp3 portal vein tumor thrombus (PVTT) face a poor prognosis and are typically ineligible for surgica…